The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis

被引:39
|
作者
Liang, Chunlian [1 ]
Li, Xiuli [1 ]
Zhang, Lin [1 ]
Cui, Dajiang [1 ]
Quan, Xiaojuan [1 ]
Yang, Weilin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Geriatr, Sch Med, Xian 710004, Shaanxi, Peoples R China
关键词
miR-153; TGF-beta; TGFBR2; Idiopathic pulmonary fibrosis; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; LUNG FIBROSIS; EXTRACELLULAR-MATRIX; LATENT TGF-BETA-1; FIBROBLASTS; ACTIVATION; EXPRESSION; RECEPTORS; DIFFERENTIATION;
D O I
10.1016/j.yexmp.2015.07.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic lung disease with an undefined etiology and no effective treatments. By binding to cell surface receptors, transforming growth factor-beta (TGF-beta) plays a pivotal role in lung fibrosis. Therefore, the screening of microRNAs (miRNAs), especially those interrupting the effects of TGF-beta, may provide information not only on the pathomechanism, but also on the treatment of this disease. In the present study, we found that miR-153 expression was dysregulated in the lungs of mice with experimental pulmonary fibrosis and TGF-beta 1 decreased miR-153 expression in pulmonary fibroblasts. Moreover, increased miR-153 levels attenuated, whereas the knock down of miR-153 promoted the pro-fibrogenic activity of TGF-beta 1, and miR-153 reduced the contractile and migratory activities of fibroblasts. In addition, TGFBR2, a transmembrane serine/threonine kinase receptor for TGF-beta, was identified as a direct target of miR-153. Furthermore, by post-transcriptional regulation of the expression of TGEBR2, phosphorylation of SMAD2/3 was also influenced by miR-153. These data suggest that miR-153 disturbs TGF-beta 1 signal transduction and its effects on fibroblast activation, acting as an anti-fibrotic element in the development of pulmonary fibrosis. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 50 条
  • [21] Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Bonovolias, Ioannis
    Sun, Qingzhu
    Tamm, Michael
    Lambers, Christopher
    Roth, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [22] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin E.
    Zhong, Jun
    Papakonstantinou, Eleni
    Karakiulakis, George
    Tamm, Michael
    Seidel, Petra
    Sun, Qingzhu
    Mandal, Jyotshna
    Lardinois, Didier
    Lambers, Christopher
    Roth, Michael
    RESPIRATORY RESEARCH, 2014, 15
  • [23] Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis
    Ishii, Daisuke
    Kawasaki, Takeshi
    Sato, Hironori
    Tatsumi, Koichiro
    Imamoto, Takuro
    Yoshioka, Keiichiro
    Abe, Mitsuhiro
    Hasegawa, Yoshinori
    Ohara, Osamu
    Suzuki, Takuji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [24] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Katrin E Hostettler
    Jun Zhong
    Eleni Papakonstantinou
    George Karakiulakis
    Michael Tamm
    Petra Seidel
    Qingzhu Sun
    Jyotshna Mandal
    Didier Lardinois
    Christopher Lambers
    Michael Roth
    Respiratory Research, 15
  • [25] MicroRNA-153 affects nasopharyngeal cancer cell viability by targeting TGF-2
    Guo, Guangliang
    Zhang, Ying
    Hu, Limin
    Bian, Xue
    ONCOLOGY LETTERS, 2019, 17 (01) : 646 - 651
  • [26] Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis
    Griffiths, K.
    Habiel, D. M.
    Jaffar, J.
    Binder, U.
    Darby, W. G.
    Hosking, C. G.
    Skerra, A.
    Westall, G. P.
    Hogaboam, C. M.
    Foley, M.
    SCIENTIFIC REPORTS, 2018, 8
  • [27] Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis
    K. Griffiths
    D. M. Habiel
    J. Jaffar
    U. Binder
    W. G. Darby
    C. G. Hosking
    A. Skerra
    G. P. Westall
    C. M. Hogaboam
    M. Foley
    Scientific Reports, 8
  • [28] Novel anti-fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in fibrosis therapy
    Inagaki, Yutaka
    Higashiyama, Reiichi
    Higashi, Kiyoshi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 85 - 88
  • [29] Anti-fibrotic effects of microRNA-9-5p and microRNA-122
    Eidelshtein, Dana
    Galun, Eithan
    Axelrod, Jonathan
    JOURNAL OF HEPATOLOGY, 2022, 77 : S474 - S474
  • [30] Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
    Sato, Seidai
    Shinohara, Shintaro
    Hayashi, Shinya
    Morizumi, Shun
    Abe, Shuichi
    Okazaki, Hiroyasu
    Chen, Yanjuan
    Goto, Hisatsugu
    Aono, Yoshinori
    Ogawa, Hirohisa
    Koyama, Kazuya
    Nishimura, Haruka
    Kawano, Hiroshi
    Toyoda, Yuko
    Uehara, Hisanori
    Nishioka, Yasuhiko
    RESPIRATORY RESEARCH, 2017, 18